GENOTROPIN
somatropin · KIT · Pfizer Laboratories Div Pfizer Inc
GENOTROPIN is a kit containing somatropin. Manufactured by Pfizer Laboratories Div Pfizer Inc.
Key Facts
- Brand Name
- GENOTROPIN
- Generic Name
- somatropin
- NDC Code (Product)
0013-2651- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Dosage Form
- KIT
- Marketing Status
- Application #
- BLA020280
- Marketing Start
- 12/20/1995
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature ( 1.1 ) • Adult: Treatment of adults with either adult onset or childhood onset GHD ( 1.2 ) 1.1 Pediatric Patients GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing [see Contraindications (4) ] . GENOTROPIN is indicated for the treatment of growth failure in pediatric patients born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years. GENOTROPIN is indicated for the treatment of growth failure associated with Turner syndrome. GENOTROPIN is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard devia…
Dosage & Administration
2 DOSAGE AND ADMINISTRATION The weekly dose should be divided into 6 or 7 subcutaneous injections. GENOTROPIN must not be injected intravenously. Therapy with GENOTROPIN should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with growth failure associated with growth hormone deficiency (GHD), Prader-Willi syndrome (PWS), Turner syndrome (TS), those who were born small for gestational age (SGA) or Idiopathic Short Stature (ISS), and adult patients with either childhood onset or adult onset GHD. GENOTROPIN should be administered subcutaneously ( 2 ) • Pediatric GHD: 0.16 to 0.24 mg/kg/week ( 2.1 ) • Prader-Willi Syndrome: 0.24 mg/kg/week ( 2.1 ) • Small for Gestational Age: Up to 0.48 mg/kg/week ( 2.1 ) • Turner Syndrome: 0.33 mg/kg/week ( 2.1 ) • Idiopathic Short Stature: up to 0.47 mg/kg/week ( 2.1 ) • Adult GHD: Either a non-weight based or a weight based dosing regimen may be followed, with doses adjusted based on treatment response and IGF-I concentrations ( 2.2 ) • Non-weight based dosing: A starting dose of approximately 0.2 mg/day (range, 0.15–0.30 mg/day) may be used without consideration of body weight, and increased gra…
Contraindications
4 CONTRAINDICATIONS • Acute Critical Illness ( 4 ) • Children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment – reports of sudden death ( 4 ) • Active Malignancy ( 4 ) • Hypersensitivity to somatropin or excipients ( 4 ) • Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy ( 4 ) • Children with closed epiphyses ( 4 ) GENOTROPIN is contraindicated in patients with: • Acute Critical Illness Treatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1) ]. • Prader-Willi Syndrome in Children Somatropin is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients [see Warnings and Precautions (5.2) ]. • Active Malignancy In general, somatropin is contraindicated in the presence of active malignancy. Any preexist…
Drug Interactions
7 DRUG INTERACTIONS Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance doses ( 7.1 , 7.2 ). • Glucocorticoid Replacement: Should be carefully adjusted ( 7.2 ) • Cytochrome P450-Metabolized Drugs: Monitor carefully if used with somatropin ( 7.3 ) • Oral Estrogen: Larger doses of somatropin may be required in women ( 7.4 ) • Insulin and/or Oral/Injectable Hypoglycemic Agents: May require adjustment ( 7.5 ) 7.1 11 β-Hydroxysteroid Dehydrogenase Type 1 The microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH and somatropin inhibit 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Introduction of somatropin treatment may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations. As a consequence, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glu…
Adverse Reactions
6 ADVERSE REACTIONS The following important adverse reactions are also described elsewhere in the labeling: • Increased mortality in patients with acute critical illness [see Warnings and Precautions (5.1) ] • Fatalities in children with Prader-Willi syndrome [see Warnings and Precautions (5.2) ] • Neoplasms [see Warnings and Precautions (5.3) ] • Glucose intolerance and diabetes mellitus [see Warnings and Precautions (5.4) ] • Intracranial hypertension [see Warnings and Precautions (5.5) ] • Severe hypersensitivity [see Warnings and Precautions (5.6) ] • Fluid retention [see Warnings and Precautions (5.7) ] • Hypoadrenalism [see Warnings and Precautions (5.8) ] • Hypothyroidism [see Warnings and Precautions (5.9) ] • Slipped capital femoral epiphysis in pediatric patients [see Warnings and Precautions (5.10) ] • Progression of preexisting scoliosis in pediatric patients [see Warnings and Precautions (5.11) ] • Otitis media and cardiovascular disorders in patients with Turner syndrome [see Warnings and Precautions (5.12) ] • Lipoatrophy [see Warnings and Precautions (5.13) ] • Pancreatitis [see Warnings and Precautions (5.15) ] Other common somatropin-related adverse reactions incl…
Frequently Asked Questions
What is GENOTROPIN used for?
GENOTROPIN contains somatropin. It is a kit taken as directed. Consult your doctor for specific uses.
Is GENOTROPIN a controlled substance?
GENOTROPIN is not classified as a controlled substance by the DEA.
What is the generic name for GENOTROPIN?
The generic name for GENOTROPIN is somatropin. There are 6 other brand versions of somatropin.
What is the NDC code for GENOTROPIN ?
The NDC (National Drug Code) for GENOTROPIN is 0013-2651, listed by Pfizer Laboratories Div Pfizer Inc.